Initiate a Phase 2 study in polycythemia vera

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 12 Nov 2024
Due: 31 Dec 2025
Delivered: by 30 Jun 2025

Deadline
Met
Late
Not met
Today

What the company said

“The Company plans to initiate a Phase 2 study in polycythemia vera (PV) in 2025”

SourceDisc Medicine, Inc. Form 8-K press release, 2024-11-12
FilingSEC filing index
Deadline as statedin 2025
Deadline used31 Dec 2025, the last day of the stated period
TypeProject
Permanent referenceKI-C-2024-IRON-002180
Cite as https://keptindex.org/c/KI-C-2024-IRON-002180/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company initiated the RESTORE-PV Phase 2 clinical trial for polycythemia vera in the first half of 2025, meeting the commitment to start the study within the 2025 calendar year.

A
Disc Medicine, Inc. 10-K filed 2026-02-26 Regulatory filing · published 26 Feb 2026 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In the first half of 2025, we initiated RESTORE-PV, a Phase 2, open-label clinical trial of DISC-3405 in participants with PV.” ✓ confirmed on the page

Market reaction: the shares moved +0.4% against the S&P 500 over the three sessions around the disclosure (25 Feb 2026 to 2 Mar 2026). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift -184 days
2 versions

Version 1 · original · stated 12 Nov 2024

Deadline 31 Dec 2025 (“in 2025”) · wording expected
Version 2 · stated 10 Jan 2025

Deadline 30 Jun 2025 (“H1 2025”) · wording expected

“Initiation of phase 2 study of DISC-3405 (anti-TMPRSS6 antibody) in polycythemia vera (PV) planned for H1 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 2 study in polycythemia vera
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.